What are the infection risks and recommended prophylactic measures at various CD4‑cell count thresholds in a patient with HIV?

CD4 Count Thresholds and Infection Prophylaxis in HIV

All HIV-infected adults should receive trimethoprim-sulfamethoxazole (TMP-SMX) double-strength tablet once daily when CD4 count falls below 200 cells/µL, which simultaneously prevents both Pneumocystis pneumonia and toxoplasmosis in seropositive patients. 1

Critical CD4 Thresholds for Prophylaxis Initiation

CD4 <200 cells/µL: Pneumocystis Pneumonia (PCP)

• TMP-SMX 800/160 mg (double-strength) once daily is the preferred regimen for all patients with CD4 <200 cells/µL, providing dual protection against PCP and toxoplasmosis. 1
• Prophylaxis is also mandatory regardless of CD4 count if the patient has unexplained fever >100°F for ≥2 weeks or oropharyngeal candidiasis. 1
• Alternative regimens when TMP-SMX is intolerable:
  • Dapsone 100 mg daily (PCP coverage only). 1
  • Atovaquone 1500 mg daily (PCP coverage only). 1
  • Aerosolized pentamidine 300 mg monthly (least preferred; no systemic or toxoplasmosis coverage). 1

CD4 <100 cells/µL: Toxoplasmosis

• For Toxoplasma-IgG-positive patients, TMP-SMX double-strength daily already provides adequate toxoplasmosis prophylaxis—no additional agent is needed. 1
• If TMP-SMX cannot be tolerated, use dapsone 50 mg daily + pyrimethamine 50 mg weekly + leucovorin 25 mg weekly for combined PCP and toxoplasmosis coverage. 1
• Toxoplasma-seronegative patients should be retested for IgG when CD4 drops below 100 cells/µL to detect seroconversion and determine prophylaxis need. 1
• Aerosolized pentamidine does not protect against toxoplasmosis and must not be used as sole prophylaxis in this CD4 range. 1

CD4 <50 cells/µL: Mycobacterium Avium Complex (MAC)

• Azithromycin 1200 mg once weekly is the preferred MAC prophylaxis due to superior adherence, fewer drug interactions with antiretrovirals, and additional protection against bacterial respiratory infections. 2
• Clarithromycin 500 mg twice daily is equally effective but has significant interactions with protease inhibitors and requires twice-daily dosing. 2
• Rifabutin 300 mg daily is second-line, requiring dose adjustments with most antiretrovirals and mandatory exclusion of active tuberculosis before initiation. 2
• Do not combine clarithromycin with rifabutin—this increases adverse effects without improving efficacy. 2
• Many experts now forgo routine MAC prophylaxis when antiretroviral therapy (ART) is started immediately and achieves rapid viral suppression. 2

Antiretroviral Therapy as Primary Prevention

• Initiate ART immediately upon HIV diagnosis, even before genotype or resistance results are available. 2
• Preferred first-line regimens:
  • Bictegravir/tenofovir alafenamide/emtricitabine, or
  • Dolutegravir + tenofovir + emtricitabine. 2
• For most opportunistic infections, start ART within 2 weeks of diagnosis. 2
• ART is the most effective strategy for preventing opportunistic infections by restoring immune function and increasing CD4 counts. 2

Discontinuing Prophylaxis After Immune Reconstitution

Prophylaxis can be safely discontinued only after sustained CD4 recovery on ART for ≥3 months with virologic suppression. 1

Infection	Discontinuation Threshold	Required Duration on ART
PCP	CD4 >200 cells/µL	≥3 months
Toxoplasmosis	CD4 >200 cells/µL	≥3 months
MAC	CD4 >100 cells/µL	≥3 months

• Restart prophylaxis immediately if CD4 falls below the original threshold: PCP/toxoplasmosis at <200 cells/µL, MAC at <50–100 cells/µL. 1, 2
• Use the nadir (lowest-ever) CD4 count to determine prophylaxis need, not the most recent count elevated by ART. 3
• Do not discontinue based on a single CD4 measurement—sustained elevation for ≥3 months is mandatory. 1

Additional Prophylaxis Considerations

Herpes Simplex Virus (HSV) / Varicella-Zoster Virus (VZV)

• Acyclovir or valacyclovir prophylaxis is strongly recommended for patients with prior HSV or VZV infection, especially when CD4 <200 cells/µL. 1

Cytomegalovirus (CMV)

• Monitor closely for CMV disease when CD4 <100 cells/µL; routine primary prophylaxis is not recommended, but dilated fundoscopic examination is advised. 1

Fungal Infections

• Fluconazole prophylaxis may be considered for CD4 <100 cells/µL in patients with recurrent candidiasis or anticipated prolonged neutropenia. 1
• Routine primary antifungal prophylaxis is not recommended for most patients. 1

Drug Interactions and Safety

• Azithromycin has fewer interactions than clarithromycin with protease inhibitors, making it the preferred macrolide. 1
• Rifabutin requires dose adjustments with most protease inhibitors and non-nucleoside reverse transcriptase inhibitors. 1, 2
• TMP-SMX has minimal interactions with integrase inhibitor-based ART, making it compatible with first-line regimens. 2
• Zidovudine should be avoided due to myelosuppression, and didanosine/stavudine should be avoided due to additive peripheral neuropathy. 1

Critical Pitfalls to Avoid

• Never use aerosolized pentamidine as first-line prophylaxis when TMP-SMX is tolerated—it lacks systemic coverage and does not prevent toxoplasmosis. 1
• Never delay PCP prophylaxis while awaiting CD4 results in patients with oropharyngeal candidiasis or prior AIDS-defining illness. 1
• Never discontinue prophylaxis prematurely—ensure sustained CD4 elevation for the full 3-month duration. 1, 3
• Always exclude active tuberculosis before starting rifabutin to avoid inducing rifampin resistance. 2
• Always rule out disseminated MAC disease clinically before initiating MAC prophylaxis. 2
• Monitor for immune reconstitution inflammatory syndrome (IRIS) after ART initiation, especially in patients with CD4 <50 cells/µL. 3

Infections Occurring at Any CD4 Level

• Tuberculosis can manifest at any CD4 count, though risk escalates significantly below 300 cells/µL. 1, 3
• Bacterial pneumonia (Streptococcus pneumoniae, Haemophilus influenzae) remains the most common pneumonia at any CD4 level. 3
• Herpes zoster and pneumococcal infections can occur even with CD4 >200 cells/µL. 3